Ro will be able to allow patient-centric primary care experiences for a broader range of illnesses and assist chronic and preventative care, using Kit's at-home, self-administered testing solutions.
FREMONT, CA: Ro, the healthcare technology company, has declared the acquisition of at-home diagnostics company Kit. The acquisition broadens the diagnostics capabilities and lab infrastructure of Ro's vertically integrated primary care platform and builds on the company's existing strengths, including nationwide telehealth, lab processing, pharmacy, and in-home testing and care services. Ro will be able to allow patient-centric primary care experiences for a broader range of illnesses and assist chronic and preventative care, using Kit's at-home, self-administered testing solutions.
Kit, also known as Kit.com, currently offers customizable, physician-ordered diagnostic tests, such as finger-prick blood assays, blood pressure testing, weight measurement tools, and more—all tailored to the patient's specific needs and delivered straight to their home. The tests are self-administered by the patient, who is led step by step by video and on-demand support via the Kit app. As soon as the results are ready, patients and providers are alerted. Kit is vertically integrated as well as processes the tests at a high-complexity, CLIA-certified, and CAP-accredited lab in San Francisco, CA, which it owns and operates.
Zachariah Reitano, co-founder and CEO of Ro, stated, "With Kit, we are adding another essential piece to our vertically-integrated primary care platform. Kit has built their own lab and a magical patient experience for the self-collection of important health data—from blood tests to saliva to blood pressure. Combining Kit with Workpath, our existing in-home care API, will enable Ro and other healthcare companies to send either a healthcare professional or test kit to a patient's home with the click of a button. Ultimately, this delivers unrivaled convenience for patients and turns the home into the exam room of the future."
